Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases

NCT02616393 is registered in ClinicalTrials.gov with Kadmon Corporation, LLC as lead sponsor.

NCT NCT02616393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02616393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Lead sponsor
Kadmon Corporation, LLC
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
April 3, 2018
Enrollment
36 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, leptomeningeal metastases, non-small cell lung cancer